Business Context and Reporting Period
This Form 8-K is a current report filed by Tocagen Inc. (not Forte Biosciences, Inc.) on April 12, 2019. The filing addresses corporate governance changes under Item 5.02 regarding the departure of an officer and the appointment of a director.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
- Officer Departure: Lori Kunkel, M.D., resigned as acting Chief Medical Officer, effective April 15, 2019.
- Director Appointment: Dr. Kunkel was re-appointed as a Class II director and a member of the Compensation Committee, effective immediately upon her resignation as an officer.
- Term: Her director term expires at the 2019 annual meeting of stockholders.
Compensation and Governance Details
Under the Company's Non-Employee Director Compensation Policy, Dr. Kunkel is eligible for:
- An annual cash retainer of $35,000 for Board service.
- An additional annual cash retainer of $5,000 for Compensation Committee service.
- Automatic annual option grants of 20,000 shares (vesting in one year), except she will not receive the initial option grant in connection with this specific re-appointment.
Dr. Kunkel has entered into the Company's standard Indemnification Agreement. The filing states there are no undisclosed transactions or arrangements requiring disclosure under Item 404(a) of Regulation S-K.
Investor Verification Checklist
- Verify the exact effective date of Dr. Kunkel's resignation as acting Chief Medical Officer (stated as April 15, 2019).
- Confirm the status of the initial equity option grant waiver for Dr. Kunkel.
- Review the Company's upcoming 2019 annual meeting schedule for Dr. Kunkel's re-election.
- Note that this filing contains no financial data; refer to the most recent 10-Q or 10-K for financial metrics.